亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

Biomarker for Inflammatory Bowel Disease

技術應用
The diagnosis of IBD using CEACAM6 as a biomarker to correlate to loss of PTPN2 activity.
詳細技術說明
None
*Abstract

Prof. Declan McCole and his colleagues at the University of California, Riverside have identified that increased levels of carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) correlate to a loss of function mutation in a protein tyrosine phosphatase non-receptor type 2 (PTPN2) gene. PTPN2 has been identified as an IBD candidate gene that protects the intestinal epithelial barrier.  Dysfunction of the PTPN2 gene, which encodes the T-cell protein tyrosine phosphatase (TCPTP) protein, contributes to alterations in the intestinal microbiome and the onset of chronic intestinal inflammation which is a symptom of IBD. Loss of function of PTPN2 has resulted in IBD-like symptoms in mice and caused the increased abundance of the intestinal pathobiont adherent-invasive Escherichia coli that binds to CEACAM6 and increases a patient’s susceptibility to IBD.
declan

Fig. 1 shows control and PTPN2-KD cell lysates with reduced protein expression of TCPTP (PTPN2) in PTPN2-deficient cells that express increased CEACAM6 protein when compared to control cells

 

*Principal Investigation

Name: Declan McCole

Department:

其他

Background

Inflammatory Bowel Disease (IBD) includes Crohn’s Disease and ulcerative colitis (UC). There is no definitive test for diagnosing IBD and its diagnosis involves a number of invasive tests such as colonoscopies, biopsies and blood tests.  Tests that screen for fecal inflammatory biomarkers  and serological markers are in development. Given that IBD is a heterogeneous disease and subsets of patients may be defined by genetic and subclinical markers that reflect specific types of inflammation, each IBD subtype represents an opportunity for individualized treatment approaches. Therefore additional biomarkers that may be added to the panel of biomarkers to improve the diagnosis of IBD are essential.


Tech ID/UC Case

29390/2018-548-0


Related Cases

2018-548-0

國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備